NR1I2 and cancer: Indeed, SPA70 was reviewed as potent and selective PXR antagonist (IC50 of 510 nM in the cell-based hPXR antagonistic assay), while inhibited PXR activities in human hepatocytes or humanized mouse models and enhanced the chemosensitivity of cancer cells, consistent with the role of PXR in drug resistance (Lin et al., 2017).